Aligos Therapeutics, Inc. (NASDAQ:ALGS - Free Report) - Investment analysts at Leerink Partnrs increased their Q2 2024 earnings per share (EPS) estimates for Aligos Therapeutics in a research note issued on Tuesday, May 7th. Leerink Partnrs analyst R. Ruiz now anticipates that the company will post earnings of ($0.16) per share for the quarter, up from their prior forecast of ($0.21). The consensus estimate for Aligos Therapeutics' current full-year earnings is ($0.83) per share. Leerink Partnrs also issued estimates for Aligos Therapeutics' Q3 2024 earnings at ($0.17) EPS, Q4 2024 earnings at ($0.19) EPS, FY2024 earnings at ($0.75) EPS and FY2025 earnings at ($0.55) EPS.
Aligos Therapeutics (NASDAQ:ALGS - Get Free Report) last announced its quarterly earnings results on Tuesday, March 12th. The company reported ($0.22) earnings per share for the quarter, topping analysts' consensus estimates of ($0.27) by $0.05. The company had revenue of $2.68 million for the quarter, compared to analysts' expectations of $3.20 million. Aligos Therapeutics had a negative net margin of 607.03% and a negative return on equity of 116.41%.
Aligos Therapeutics Price Performance
ALGS stock traded down $0.05 during trading hours on Friday, reaching $0.73. 184,447 shares of the stock were exchanged, compared to its average volume of 331,560. The company has a market cap of $55.26 million, a price-to-earnings ratio of -0.46 and a beta of 2.37. The firm's 50-day moving average is $0.90 and its 200-day moving average is $0.77. Aligos Therapeutics has a 12 month low of $0.54 and a 12 month high of $1.34.
Institutional Investors Weigh In On Aligos Therapeutics
Institutional investors have recently modified their holdings of the business. Newtyn Management LLC lifted its holdings in shares of Aligos Therapeutics by 2.2% in the third quarter. Newtyn Management LLC now owns 920,000 shares of the company's stock worth $687,000 after acquiring an additional 20,000 shares during the last quarter. Vanguard Group Inc. boosted its position in Aligos Therapeutics by 1.6% in the third quarter. Vanguard Group Inc. now owns 1,010,617 shares of the company's stock valued at $755,000 after buying an additional 15,905 shares in the last quarter. Acadian Asset Management LLC boosted its position in Aligos Therapeutics by 17.6% in the first quarter. Acadian Asset Management LLC now owns 657,995 shares of the company's stock valued at $644,000 after buying an additional 98,628 shares in the last quarter. Opaleye Management Inc. bought a new stake in shares of Aligos Therapeutics during the fourth quarter worth $861,000. Finally, Altitude Crest Partners Inc. acquired a new position in shares of Aligos Therapeutics during the fourth quarter worth $1,889,000. Institutional investors own 60.43% of the company's stock.
About Aligos Therapeutics
(
Get Free Report)
Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).
See Also
Before you consider Aligos Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aligos Therapeutics wasn't on the list.
While Aligos Therapeutics currently has a "hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
